Prof. Angus Dalgleish is the foundation professor of oncology at St. George’s University of London. He has published seminal papers on HIV and its CD4 receptor and mechanisms of pathogens. Together with colleagues in Cologne, he developed the Lenalidomide programme, having researched and used Thalidomide in new clinical applications. He received the Lederberg prize for this work in 2011. He has pioneered cancer vaccines and immunotherapy in the UK, and is now focussing on IMM-101 as a major immune modulator. He also as major research projects in LDN and the cannabinoids. He is a fellow of the Royal College of Physicians (UK and Australia), Pathologists and of the Academy of Medical Sciences. He has published over 400 papers and co-edited five text books.